Siftr Bio is developing precision therapeutics that utilize targeted delivery systems to minimize side effects in cancer treatment. The company addresses the need for highly specific therapies that improve patient outcomes while reducing the toxicity associated with conventional cancer drugs.
Funding
Funding not disclosed
Founders
Product
Problem
Conventional cancer treatments often lack specificity, leading to systemic toxicity and adverse side effects that diminish patient quality of life and limit therapeutic efficacy. The challenge lies in delivering cytotoxic drugs selectively to tumor cells while sparing healthy tissues.
Solution
Siftr Bio is developing precision therapeutics that leverage targeted delivery systems to enhance the specificity of cancer treatments and minimize off-target effects. Their approach focuses on encapsulating therapeutic payloads within biocompatible carriers engineered to selectively bind to cancer cells. This targeted delivery aims to concentrate the drug's effect within the tumor microenvironment, reducing systemic exposure and improving the therapeutic index. By increasing the precision of drug delivery, Siftr Bio seeks to improve patient outcomes and reduce the debilitating side effects associated with traditional chemotherapy and radiation.
Target Audience
Siftr Bio's primary target audience includes oncology researchers, pharmaceutical companies, and ultimately, cancer patients seeking more effective and less toxic treatment options.
Features
- Targeted drug delivery system for selective binding to cancer cells
- Encapsulation of therapeutic payloads within biocompatible carriers
- Enhanced drug concentration within the tumor microenvironment
- Reduced systemic exposure and off-target effects